

Resource Summary Report

Generated by [kravitz2](#) on Sep 5, 2026

QuantoBio

RRID:SCR_012582

Type: Tool

Proper Citation

QuantoBio (RRID:SCR_012582)

Resource Information

URL: <http://www.quantobio.com/en/>

Proper Citation: QuantoBio (RRID:SCR_012582)

Description: Located at Beijing Economic and Technological Development Area, Beijing, China, was founded by former employees from Invitrogen/Biosource and BD PharMingen and researchers at US universities in September 2009. QuantoBio focuses on developing and manufacturing high quality reagents on the research on immunology, cell biology, cancer, inflammation and related diseases for the market in the World as well as China. The product portfolios include immunoassays, recombinant bioactive proteins, antibodies on various applications including flow cytometry, Western blotting and Immunohistochemistry, microRNA profiling and assay kits and other cutting-edge research reagents. The vigorous product development combines internal product development, technology licensing, and collaborations with research laboratories worldwide. With rich experience and knowledge in product development, we offer the ranges of custom services on immunoassay and antibody developments, recombinant protein expression and bioassays, microRNA profiling, microRNA overexpression and knock-down.

Abbreviations: QuantoBio

Resource Type: commercial organization

Resource Name: QuantoBio

Resource ID: SCR_012582

Alternate IDs: SciEx_4987

Old URLs: <http://www.scienceexchange.com/facilities/quantobio>

Record Creation Time: 20220129T080311+0000

Record Last Update: 20260903T235150+0000

Ratings and Alerts

No rating or validation information has been found for QuantoBio.

No alerts have been found for QuantoBio.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Ouyang Z, et al. (2025) Azithromycin-loaded PLGA microspheres coated with silk fibroin ameliorate inflammation and promote periodontal tissue regeneration. *Regenerative biomaterials*, 12, rbae146.

Liu S, et al. (2025) Significant correlations of upregulated MPO expression with cytokine imbalance in ankylosing spondylitis patients and the inhibitory effect mediated by mesenchymal stem cells. *BMC musculoskeletal disorders*, 26(1), 212.

Zhang DY, et al. (2025) A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity. *Journal of translational medicine*, 23(1), 53.

Rombaut B, et al. (2024) Early Inhibition of Phosphodiesterase 4B (PDE4B) Instills Cognitive Resilience in APPswe/PS1dE9 Mice. *Cells*, 13(12).

Yang X, et al. (2024) Peripheral CD4+ T cells correlate with response and survival in patients with advanced non-small cell lung cancer receiving chemo-immunotherapy. *Frontiers in immunology*, 15, 1364507.

Wu W, et al. (2024) Cerebrospinal fluid neurofilament light chain levels in children with acquired demyelinating syndrome. *Frontiers in pediatrics*, 12, 1467020.

Avsieich E, et al. (2024) Pancreatic Neuroendocrine Tumor: The Case Report of a Patient with Germline FANCD2 Mutation and Tumor Analysis Using Single-Cell RNA Sequencing. *Journal of clinical medicine*, 13(24).

Gu Y, et al. (2024) M2 macrophage infusion ameliorates diabetic glomerulopathy via the JAK2/STAT3 pathway in db/db mice. *Renal failure*, 46(2), 2378210.

Yuan Y, et al. (2024) Inflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy. *Frontiers in immunology*, 15, 1367252.

Li Y, et al. (2024) Translational selenium nanoparticles boost GPx1 activation to reverse HAdV-14 virus-induced oxidative damage. *Bioactive materials*, 38, 276.

Cheng LS, et al. (2023) An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. *Cellular & molecular biology letters*, 28(1), 47.

Ma D, et al. (2023) Immunomodulatory effects of umbilical mesenchymal stem cell-derived exosomes on CD4+ T cells in patients with primary Sjögren's syndrome. *Inflammopharmacology*, 31(4), 1823.

Peng H, et al. (2023) Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination. *Microorganisms*, 11(4).

Xue J, et al. (2022) Human umbilical cord-derived mesenchymal stem cells alleviate insulin resistance in diet-induced obese mice via an interaction with splenocytes. *Stem cell research & therapy*, 13(1), 109.

Zhu J, et al. (2021) The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. *Cancer medicine*, 10(22), 7977.

Ho JY, et al. (2021) Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. *Molecular therapy. Methods & clinical development*, 21, 237.

Xu K, et al. (2021) Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles ameliorate collagen-induced arthritis via immunomodulatory T lymphocytes. *Molecular immunology*, 135, 36.

Wang Z, et al. (2021) IP-10 Promotes Latent HIV Infection in Resting Memory CD4+ T Cells via LIMK-Cofilin Pathway. *Frontiers in immunology*, 12, 656663.

Yan L, et al. (2021) Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma. *Cancer medicine*, 10(2), 563.

Miao M, et al. (2021) Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. *Arthritis research & therapy*, 23(1), 167.